Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009 May 15;11(3):167. doi: 10.1007/s11906-009-0030-9

Left ventricular hypertrophy and renin-angiotensin system blockade

Brett R Cowan 1,✉, Alistair A Young
PMCID: PMC7101545  PMID: 19442324

Abstract

The renin-angiotensin system (RAS), an important control system for blood pressure and intravascular volume, also causes left ventricular hypertrophy (LVH) and fibrosis. The main causal mechanism is the increase in blood pressure, which leads to increased left ventricular wall stress; however, aldosterone release from the adrenals and (more controversially) the direct action of angiotensin II on the cardiomyocytes also play a role. Large clinical trials evaluating the blockade of the RAS with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have demonstrated an ability to prevent progression and induce regression of left ventricular mass, thereby reducing the significant and independent cardiovascular risk conferred by LVH. Regression of left ventricular mass is also achieved by other medication classes, but the RAS blockers have an additional beneficial effect for the same blood pressure reduction, for which the mechanism is not entirely clear. Studies comparing the efficacy of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers to achieve LVH regression have not demonstrated any clear benefit of one class over the other.

Keywords: Aldosterone, Left Ventricular Hypertrophy, Losartan, Ventricular Hypertrophy, Left Ventricular Mass

References and Recommended Reading

  • 1.Kearney P., Whelton M., Reynolds K., et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–19. doi: 10.1097/00004872-200401000-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Matchar D., McCrory D., Orlando L., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16–29. doi: 10.7326/0003-4819-148-1-200801010-00189. [DOI] [PubMed] [Google Scholar]
  • 3.McMullen J., Jennings G. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharm Physiol. 2007;34:255–262. doi: 10.1111/j.1440-1681.2007.04585.x. [DOI] [PubMed] [Google Scholar]
  • 4.Agabiti-Rosei E., Muiesan M.L., Salvetti M. New approaches to the assessment of left ventricular hypertrophy. Ther Adv Cardiovasc Dis. 2007;1:119–128. doi: 10.1177/1753944707086350. [DOI] [PubMed] [Google Scholar]
  • 5.Bottini P., Carr A., Prisant M., et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995;8:221–228. doi: 10.1016/0895-7061(94)00178-E. [DOI] [PubMed] [Google Scholar]
  • 6.Young A., Cowan B., Thrupp S., et al. Left ventricular mass and volume: fast calculation with guide-point modeling on MR images. Radiology. 2000;216:597–602. doi: 10.1148/radiology.216.2.r00au14597. [DOI] [PubMed] [Google Scholar]
  • 7.Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. Eur J Echocardiography. 2006;7:79–108. doi: 10.1016/j.euje.2005.12.014. [DOI] [PubMed] [Google Scholar]
  • 8.Levy D., Garrison R., Savage D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566. doi: 10.1056/NEJM199005313222203. [DOI] [PubMed] [Google Scholar]
  • 9.Schillaci G., Verdecchia P., Porcellati C., et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580–586. doi: 10.1161/01.hyp.35.2.580. [DOI] [PubMed] [Google Scholar]
  • 10.Vakili B.A., Okin P.M., Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141:334–341. doi: 10.1067/mhj.2001.113218. [DOI] [PubMed] [Google Scholar]
  • 11.Ghali J., Liao Y., Cooper R. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol. 1998;31:1635–1640. doi: 10.1016/S0735-1097(98)00131-4. [DOI] [PubMed] [Google Scholar]
  • 12.Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48–54. doi: 10.1161/01.cir.97.1.48. [DOI] [PubMed] [Google Scholar]
  • 13.Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615–1621. doi: 10.1161/hc3901.096700. [DOI] [PubMed] [Google Scholar]
  • 14.Tigerstedt R., Bergman P. Niere und kreislauf. Skand Arch Physiol. 1898;8:223–271. [Google Scholar]
  • 15.Wolf G. “The road not taken”: role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant. 2002;17:195–198. doi: 10.1093/ndt/17.2.195. [DOI] [PubMed] [Google Scholar]
  • 16.Bader M., Ganten D. Update on tissue renin-angiotensin systems. J Mol Med. 2008;86:615–621. doi: 10.1007/s00109-008-0336-0. [DOI] [PubMed] [Google Scholar]
  • 17.Donoghue M., Hsieh F., Baronas E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87:E1–E9. doi: 10.1161/01.res.87.5.e1. [DOI] [PubMed] [Google Scholar]
  • 18.Santos R., Ferreira A. Angiotensin-(1–7) and the reninangiotensin system. Curr Opin Nephrol Hypertension. 2007;16:122–128. doi: 10.1097/MNH.0b013e328031f362. [DOI] [PubMed] [Google Scholar]
  • 19.Grobe J., Mecca A., Lingis M., et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7) Am J Physiol Heart Circ Physiol. 2007;292:736–742. doi: 10.1152/ajpheart.00937.2006. [DOI] [PubMed] [Google Scholar]
  • 20.Santos R.A., Ferreira A.J., Nadu A.P., et al. Expression of an angiotensin-(1–7)-producing fusion protein produces cardio-protective effects in rats. Physiol Genomics. 2004;17:292–299. doi: 10.1152/physiolgenomics.00227.2003. [DOI] [PubMed] [Google Scholar]
  • 21.Santos R.A., Castro C.H., Gava E., et al. Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor Mas knockout mice. Hypertension. 2006;47:996–1002. doi: 10.1161/01.HYP.0000215289.51180.5c. [DOI] [PubMed] [Google Scholar]
  • 22.Lorell B., Carabello B. Left ventricular hypertrophy: pathogenesis, detection and prognosis. Circulation. 2000;102:470–479. doi: 10.1161/01.cir.102.4.470. [DOI] [PubMed] [Google Scholar]
  • 23.Mehta P., Griendling K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82–C97. doi: 10.1152/ajpcell.00287.2006. [DOI] [PubMed] [Google Scholar]
  • 24.Reudelhuber T., Bernstein K., Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension. 2007;49:1196–1201. doi: 10.1161/HYPERTENSIONAHA.106.075085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Mazzolai L., Nussberger J., Aubert J., et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension. 1998;31:1324–1330. doi: 10.1161/01.hyp.31.6.1324. [DOI] [PubMed] [Google Scholar]
  • 26.Xiao H., Fuchs S., Campbell D., et al. Mice with cardiacrestricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol. 2004;165:1019–1032. doi: 10.1016/S0002-9440(10)63363-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.van Kats J., Methot D., Paradis P., et al. Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice: direct and indirect effects of angiotensin II on the heart. J Biol Chem. 2001;276:44012–44017. doi: 10.1074/jbc.M106132200. [DOI] [PubMed] [Google Scholar]
  • 28.Paradis P., Dali-Youcef N., Paradis F.W., et al. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A. 2000;97:931–936. doi: 10.1073/pnas.97.2.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Crowley S., Gurley S., Herrera M., et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103:17985–17990. doi: 10.1073/pnas.0605545103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Billet S., Aguilar F., Baudry C., Clauser E. Role of angiotensin II AT1 receptor activation in cardiovascular disease. Kidney Int. 2008;74:1379–1384. doi: 10.1038/ki.2008.358. [DOI] [PubMed] [Google Scholar]
  • 31.Rossi G., Sacchetto A., Visentin P., et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039–1045. doi: 10.1161/01.hyp.27.5.1039. [DOI] [PubMed] [Google Scholar]
  • 32.Delles C., Schmidt B., Muller H., et al. Functional relevance of aldosterone for the determination of left ventricular mass. Am J Cardiol. 2003;91:297–301. doi: 10.1016/S0002-9149(02)03158-2. [DOI] [PubMed] [Google Scholar]
  • 33.Marney A., Brown N. Aldosterone and end-organ damage. Clin Sci. 2007;113:267–278. doi: 10.1042/CS20070123. [DOI] [PubMed] [Google Scholar]
  • 34.Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234–242. doi: 10.7326/0003-4819-117-3-234. [DOI] [PubMed] [Google Scholar]
  • 35.Müller D.N., Derer W., Dechend R. Aliskiren—mode of action and preclinical data. J Mol Med. 2008;86:659–662. doi: 10.1007/s00109-008-0330-6. [DOI] [PubMed] [Google Scholar]
  • 36.Brown M., Coltart J., Gunewardena K., et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci. 2004;107:167–173. doi: 10.1042/CS20030381. [DOI] [PubMed] [Google Scholar]
  • 37.Ambuhol P., Tissot A., Fulurija A., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25:63–72. doi: 10.1097/HJH.0b013e32800ff5d6. [DOI] [PubMed] [Google Scholar]
  • 38.Klingbeil A., Schneider M., Martus P., et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41–46. doi: 10.1016/S0002-9343(03)00158-X. [DOI] [PubMed] [Google Scholar]
  • 39.Dahlöf B., Devereux R., Kjeldsen S., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003. doi: 10.1016/S0140-6736(02)08089-3. [DOI] [PubMed] [Google Scholar]
  • 40.Devereux R.B., Dahlöf B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456–1462. doi: 10.1161/01.CIR.0000141573.44737.5A. [DOI] [PubMed] [Google Scholar]
  • 41.O’Rourke M.F., Safar M.E. Letter regarding article by Devereux et al, “Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial”. Circulation. 2005;111:e377. doi: 10.1161/CIRCULATIONAHA.104.525519. [DOI] [PubMed] [Google Scholar]
  • 42.Hirata K., Vlachopoulos C., Adji A., O’Rourke M.F. Benefits from angiotensin-converting enzyme inhibitor “beyond blood pressure lowering”: beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23:551–556. doi: 10.1097/01.hjh.0000160211.56103.48. [DOI] [PubMed] [Google Scholar]
  • 43.The ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Eng J Med. 2008;358:1547–1559. doi: 10.1056/NEJMoa0801317. [DOI] [PubMed] [Google Scholar]
  • 44.Pitt B., Zannad F., Remme W., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001. [DOI] [PubMed] [Google Scholar]
  • 45.Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit in spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES) Circulation. 2000;102:2700–2706. doi: 10.1161/01.cir.102.22.2700. [DOI] [PubMed] [Google Scholar]
  • 46.Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–1838. doi: 10.1161/01.CIR.0000091405.00772.6E. [DOI] [PubMed] [Google Scholar]
  • 47.Devereux R., Palmieri V., Sharpe N., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation. 2001;104:1248–1254. doi: 10.1161/hc3601.095927. [DOI] [PubMed] [Google Scholar]

Articles from Current Hypertension Reports are provided here courtesy of Nature Publishing Group

RESOURCES